Core Viewpoint - The Molina Healthcare class action lawsuit alleges that the company and its executives violated the Securities Exchange Act of 1934 by failing to disclose critical adverse information regarding its financial health and operational challenges during the specified class period [1][4]. Group 1: Class Action Details - The class action lawsuit is titled Hindlemann v. Molina Healthcare, Inc., and covers purchasers of Molina Healthcare securities from February 5, 2025, to July 23, 2025, with a deadline of December 2, 2025, for seeking lead plaintiff status [1]. - The lawsuit claims that Molina Healthcare did not disclose material facts about its medical cost trend assumptions and the dislocation between premium rates and medical costs [4]. Group 2: Financial Performance and Impact - On July 7, 2025, Molina Healthcare reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines, leading to a 10.2% cut in earnings guidance [5]. - Following the financial results announcement on July 23, 2025, Molina Healthcare reported a GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year-over-year, and revised its full-year 2025 adjusted earnings guidance to no less than $19.00 per diluted share [6]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Molina Healthcare securities during the class period to seek lead plaintiff status, which involves directing the class action lawsuit on behalf of all class members [7]. - Investors are not required to serve as lead plaintiff to share in any potential recovery from the lawsuit [7]. Group 4: Company Overview - Molina Healthcare provides managed healthcare services primarily to low-income families and individuals under Medicaid and Medicare programs [3].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Molina Healthcare, Inc. securities, alleging that the company failed to disclose material adverse facts during the Class Period from February 5, 2025, to July 23, 2025 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Molina Healthcare did not disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - The lawsuit alleges that Molina's near-term growth relied on a lack of utilization of various health services, which was not communicated to investors [5]. - As a result of these undisclosed facts, Molina's financial guidance for fiscal year 2025 was likely to be significantly reduced, misleading investors about the company's business prospects [5]. Group 2: Participation Information - Investors who purchased Molina securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in terms of the number of securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A securities class action lawsuit has been filed against Molina Healthcare, Inc. for allegedly making false and misleading statements regarding its financial health and operational assumptions during the specified Class Period from February 5, 2025, to July 23, 2025 [1][2]. Allegations Against Defendants - The complaint claims that Molina's management failed to disclose material adverse facts about the company's medical cost trend assumptions [2]. - It is alleged that there was a dislocation between Molina's premium rates and medical cost trends, impacting the company's financial guidance for fiscal year 2025 [2]. - The lawsuit suggests that Molina's near-term growth relied on a lack of utilization of various health services, which was not adequately communicated to investors [2]. - As a result of these issues, the positive statements made by Molina's management regarding the company's business and prospects were misleading and lacked a reasonable basis [2]. Lead Plaintiff Process - Investors in Molina have until December 2, 2025, to seek appointment as a lead plaintiff representative in the class action [3]. - The lead plaintiff will represent the interests of all class members and will select legal counsel to direct the litigation [3]. - Participation as a lead plaintiff does not affect an investor's ability to share in any potential recovery from the lawsuit [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them before the December 2, 2025 deadline for lead plaintiff applications in a federal securities class action [1][3]. Group 1: Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements regarding the company's medical cost trend assumptions and failed to disclose adverse facts impacting financial guidance [3]. - Specific issues highlighted include a dislocation between premium rates and medical costs, reliance on low utilization of various health services, and the likelihood of significant cuts to financial guidance for fiscal year 2025 [3]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below expectations, leading to a 10.2% cut in full-year earnings guidance [4]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025, amid heavy trading volume [4]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting guidance to no less than $19.00 per diluted share [5][6]. - This led to a significant stock price drop of $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025, also on unusually heavy trading volume [6].

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company that provides managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was able to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2%, revising it to a range of $21.50 to $22.50 per share [4]. - Following further revelations on July 23, 2025, regarding a challenging medical cost trend environment, Molina's stock price fell by $32.03 per share, or 16.8%, from $190.25 to $158.22 [4].

Core Viewpoint - The Molina Healthcare class action lawsuit alleges that the company and its executives failed to disclose critical information regarding financial performance and medical cost trends, leading to significant stock price declines during the class period [1][3][4]. Summary by Sections Class Action Details - The class action lawsuit is titled Hindlemann v. Molina Healthcare, Inc., and covers purchasers of Molina Healthcare securities from February 5, 2025, to July 23, 2025, with a deadline of December 2, 2025, for lead plaintiff applications [1][2]. Allegations Against Molina Healthcare - The lawsuit claims that Molina Healthcare did not disclose adverse facts about its medical cost trend assumptions, the dislocation between premium rates and medical costs, and the dependency of near-term growth on low utilization of various health services [3]. - It is alleged that Molina Healthcare's financial guidance for fiscal year 2025 was likely to be cut due to these undisclosed issues [3]. Financial Performance and Stock Impact - On July 7, 2025, Molina Healthcare reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines, leading to a 10.2% cut in earnings guidance [4]. - Following the financial results announcement on July 23, 2025, Molina Healthcare reported GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year-over-year, and revised its full-year 2025 adjusted earnings expectation to no less than $19.00 per diluted share, resulting in a nearly 17% drop in stock price [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Molina Healthcare securities during the class period to seek lead plaintiff status, which involves directing the class action lawsuit on behalf of all class members [6]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief for investors [7][8].

Group 1 - A securities class action lawsuit has been filed against Molina Healthcare, Inc. on behalf of investors who purchased or acquired Molina securities between February 5, 2025, and July 23, 2025 [1] - The lead plaintiff deadline for the lawsuit is set for December 2, 2025 [1]

Core Viewpoint - Investors in Molina Healthcare, Inc. have the opportunity to lead a securities fraud class action lawsuit due to undisclosed adverse facts affecting the company's financial guidance and operations [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from February 5, 2025, to July 23, 2025, Molina failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [2]. - It is claimed that Molina's growth was reliant on limited utilization of various health services, which could lead to a significant reduction in the company's financial guidance for fiscal year 2025 [2]. Investor Participation - Investors who suffered losses related to Molina Healthcare are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for December 2, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to participate [3][4].

Core Viewpoint - Class action lawsuits have been filed against RCI Hospitality Holdings, Fortinet, and Molina Healthcare, alleging that these companies made materially false and misleading statements regarding their business operations and prospects, leading to investor losses [2][3][4]. RCI Hospitality Holdings, Inc. (NASDAQ: RICK) - Class period spans from December 15, 2021, to September 16, 2025, with a lead plaintiff deadline of November 20, 2025 [2]. - Allegations include engagement in tax fraud, bribery to cover up tax fraud, and understatement of legal risks, resulting in misleading positive statements about the company's business [2]. Fortinet, Inc. (NASDAQ: FTNT) - Class period spans from November 8, 2024, to August 6, 2025, with a lead plaintiff deadline of November 21, 2025 [3]. - Allegations include misrepresentation of the refresh cycle's profitability, lack of clarity on upgradeable FortiGate firewalls, and misleading statements about the momentum of the refresh, leading to materially misleading information about the company's prospects [3]. Molina Healthcare, Inc. (NYSE: MOH) - Class period spans from February 5, 2025, to July 23, 2025, with a lead plaintiff deadline of December 2, 2025 [4]. - Allegations include failure to disclose adverse facts regarding medical cost trend assumptions, dependency on low utilization of services for growth, and likelihood of cutting financial guidance for fiscal year 2025, resulting in misleading positive statements about the company's operations [4].

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The case is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company providing managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was monitoring utilization patterns to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2%, revising it to a range of $21.50 to $22.50 per share [4]. - On July 23, 2025, Molina adjusted its full-year 2025 earnings expectation to no less than $19.00 per diluted share, citing a challenging medical cost trend environment [4]. - Following this announcement, Molina's stock price fell by $32.03 per share, or 16.8%, from $190.25 to $158.22 [4].